DEA Drops Enigmatic Decision on Nurse Practitioner Balisky
Published Date: 12/19/2025
Notice
Summary
Timothy Balisky, a nurse practitioner from North Carolina, lost his DEA registration because he no longer has the legal right to handle controlled substances in his state. He didn’t ask for a hearing to challenge this, so the DEA officially revoked his registration as of July 31, 2025. This means he can’t prescribe or manage controlled drugs anymore, affecting his professional practice and patients relying on him.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA Registration Revoked
If you are a patient of Timothy Balisky, N.P., he can no longer prescribe, administer, dispense, or otherwise handle controlled substances for you. The Drug Enforcement Administration revoked DEA Certificate of Registration No. MB7242352, and that revocation is effective January 20, 2026.
Renewals and New Registrations Denied
Any pending applications by Timothy Balisky to renew, modify, or obtain additional DEA registration in North Carolina are denied. The Order denying pending applications is effective January 20, 2026.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08587 — Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.
ANI Pharmaceuticals wants to import certain controlled drugs like Levorphanol and Tapentadol. People who make or use these drugs can share their thoughts or ask for a hearing by June 3, 2026. This move could affect drug availability and regulation, so keep an eye on the deadline to have your say!
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
Previous / Next Documents
Previous: 2025-23474 — Agency Information Collection Activities; Proposed Collection; Comment Request; Required Warnings for Cigarette Packages and Advertisements
The FDA wants your thoughts on how they collect info about cigarette warning labels on packs and ads. This affects tobacco companies who must follow these rules and helps keep smokers informed. You’ve got until February 17, 2026, to share your comments—no cost to you, just your voice!
Next: 2025-23476 — Qualification of Drivers; Exemption Applications; Hearing
The FMCSA is renewing special permissions for 21 hard of hearing or deaf drivers, letting them keep driving big trucks across state lines despite the usual hearing rules. These renewals keep things rolling smoothly without extra costs or delays. If you want to share your thoughts, make sure to comment by January 20, 2026!